Navigation Links
Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Date:6/26/2008

ATLANTA, June 26 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim month three safety and efficacy results from the first human pharmacokinetic (PK) study of Medidur(TM) FA, which Alimera Sciences intends to market under the tradename Iluvien(TM), if approved by the U.S. Food and Drug Administration.

This 36-month, open-label Phase 2 study, running concurrently with the pivotal Phase 3 FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), is designed primarily to assess systemic exposure of the corticosteroid, fluocinolone acetonide (FA), after administration of Iluvien in diabetic macular edema (DME) patients. Secondarily, the study is designed to provide information on the safety and efficacy of Iluvien in a DME population. A total of 37 subjects were enrolled in this trial, 20 patients on the low dose (an approximate 0.23 microgram per day dose) of Iluvien, and 17 patients on the high dose (an approximate 0.45 microgram per day dose) with the same inclusion/exclusion criteria as the ongoing Phase 3 FAME Study.

Iluvien is an intravitreal insert being developed for the treatment of DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 24 months for the low dose and up to 36 months for the high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.

This three-month interim readout from the PK Study indicated 20 percent of the low dose patients and 18 percent of the high dose patients showed an improvement in best-corrected visual acuity
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)... , MONTVALE, N.J., Nov. 19 /PRNewswire-First...EMY ) today announced that it has achieved the enr...54, its lead alpha-7 nicotinic receptor agonist, i...ia (CIAS). The Company has randomized 212 patient...payment from its partner Roche. Memory Pharmaceut...
(Date:11/18/2008)...gton Medical Resources (AMR), a,provider of premi...diagnostic,imaging industries, finds that over $1...he U.S. during the third quarter of 2008. Privigen...in (IVIG) and was launched in the first,quarter o...lasma of thousands,of donors and is used to treat...
(Date:11/18/2008)...d, elderly AML patients , , PRINCETON, N.J....today announced that the first patient has been tr...X-351 (Cytarabine:Daunorubicin) Liposome Injection...ukemia (AML). , , The first patient was enr...llege of Cornell University and New York Presbyte...
(Date:11/13/2008)...ut Risk of Heart Attacks, Deaths, RESTON, Va., No...sease,is the leading cause of death among American...ons of dollars and causing untold suffering. Now,t... - even among those who,weren,t thought to be at r...le could cut their risk of a,heart attack, stroke ...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Seniors Can Be Heartened by New Study on Statins 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 1Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 3DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 1DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 2DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 3Oral Contraceptives Cut Ovarian Cancer Risk 10111 1Oral Contraceptives Cut Ovarian Cancer Risk 10111 2Oral Contraceptives Cut Ovarian Cancer Risk 10111 3Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 1Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 2Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 3
..., Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc....e recent Phase II proof of,concept clinical trial ...nical trial evaluating ACAPODENE(R) (toremifene ci...fects of androgen,deprivation therapy (ADT) will b... the American Society of Clinical Oncology being,h...
...RSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ -...nnounce results from the,Phase 1 trial of its patc...arkets open tomorrow. A conference call and live,w...rrow to discuss,the results. , Conference Call Det...May 25, 2007 at 8:30,a.m. Eastern Time via phone, ...
Other Medicine Technology:GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:11/21/2008)... work together to stop abusive behavior, experts s...-- Behavior that was once dismissed as "kids being...mounting research shows the negative effects on bo...ionals, schools, parents and even kids themselves ...ning behavior. , "Bullying shouldn,t be consid...
(Date:11/21/2008)...ire-FirstCall/ -- Heska Corporation,(Nasdaq: HS...rk Society of,Security Analysts, 12th Annual Biot..., 2008 at 1177 Avenue of the Americas, 2nd Floor i...begin at 9:35 a.m. Eastern Time (7:35 a.m.,Mounta...d for two weeks,following the presentation throug...
(Date:11/21/2008)...ovel technique to combat cancer, study says, ,...lgian researchers have discovered that some cancer...and this might lead to new treatments that starve ...ate, all cells in the body need to produce energy....s that requires oxygen. Compared with normal cells...
(Date:11/21/2008)...re-USNewswire/ -- U.S. News & World Report and...A) ranked BlueChoice(R) HealthPlan of South Caroli...(TM), published in U.S. News & World Report,s ...anking ranks the nation,s best health plans based ...accreditation scores. NCQA and U.S. News & Wor...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...d environmental changes have caused drastic increa...ent 17% of the childhood cancer cases.// 77,111 c... 1997 in 15 European countries were analyzed in th... was an increase by an average of 1.1% a year in t...
... drug that is being developed for multiple scleros...ggests that the experimental drug fingolimod might...ultiple sclerosis. It was also reported in the stu...studies could show satisfactorily that the patient...
...nary problems than white men, but are only half as...s conducted on over 8,000 men has been published i...nternational, states that South Asian men suffer f...than white men, but are less likely to seek help. ...
...ts facing major losses to outsource medical transc...ounds a year.// Around 60 specialist posts are to ... in Leeds are reported to be facing debts of 84 mi...in Britain have already outsourced such work to In...
Other Medicine News:Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2Health News:An Experimental New Drug Might Be Effective In Treating MS 2Health News:South Asian Men Have More Urinary Problems Than White Men 2Health News:Leeds Hospitals to Outsource Medical Transcription Work to India 2
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
...ted Clinical Applications:, ,Cool Aerosol Therapy...th open system devices such as aerosol masks, face...de only limited FIO2 and limited flow. The design ...dental dilution with room air or high FIO2 due to ...
...w PARI TREK™ Compact Compressor is for activ...ts anywhere and everywhere. The compressor is smal...ower source optionsworldwide AC compatibility (100...rmit patients the freedom to take aerosol treatmen...
...ucing Quieter Compressed Air., ,Allied Healthcare...so much quieter than other air compressors that yo... too. The PCS 414 features a durable, mar-resistan..., the unit weighs only 26.5 pounds. The PCS 414 ha...
Medicine Products: